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RUNNING TITLE
Myc induces senescence via a DDR and stromal TGF-β
2SUMMARY
Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive
barrier in early cancer development, at least in part, via an oncogene-evoked DNA
damage response (DDR). In contrast, Myc activation – although producing a DDR
as well – is known to primarily elicit an apoptotic countermeasure. Using the Eµ-
myc transgenic mouse lymphoma model, we show here in vivo that apoptotic
lymphoma cells activate macrophages to secrete transforming growth factor–β
(TGF-β) as a critical non-cell-autonomous inducer of cellular senescence.
Accordingly, neutralization of TGF-β action, like genetic inactivation of the
senescence-related histone methyltransferase Suv39h1, significantly accelerates
Myc-driven tumor development via cancellation of cellular senescence. These
findings, recapitulated in human aggressive B-cell lymphomas, demonstrate that
tumor-prompted stroma-derived signals may limit tumorigenesis by feedback
senescence induction.
HIGHLIGHTS
• Myc drives tumor-limiting senescence via cell-autonomous and non-cell-
autonomous ways
• The histone methyltransferase Suv39h1 is essential for Myc-induced senescence
• Apoptotic body-engulfing macrophages secrete TGF-β that induces tumor
senescence
• These tumor/host interactions were recapitulated in human aggressive B-cell
lymphomas
3GRAPHICAL ABSTRACT
is enclosed.
SIGNIFICANCE
Cancer entities with constitutive Myc expression, among them aggressive B-cell
lymphomas, typically display high levels of apoptosis. So far, cellular senescence as
another oncogene-inducible safeguard program has been recognized in
RAS/BRAF-driven scenarios, but not as a bona fide Myc-evoked anti-cancer
mechanism. Utilizing the genetically tractable Eµ-myc  transgenic mouse
lymphoma model and presenting supportive evidence from human aggressive B-
cell lymphoma samples, this study establishes a novel network of tumor/host
immune cell interactions in which apoptotic tumor cells launch a paracrine
response in non-malignant bystanders that limits lymphomagenesis by cellular
senescence. Our data expand the relevance of oncogene-induced senescence to
Myc-driven cancers, and highlight the tumor stroma as a critical contributor and
potential therapeutic target in this process.
4INTRODUCTION
Mitogenic oncogenes provoke checkpoint-mediated cellular countermeasures such
as apoptosis or premature senescence, a terminal G1 arrest involving the p53 and
p16INK4a tumor suppressors that is characterized by typical transcriptional, biochemical
and morphological alterations (Campisi and d'Adda di Fagagna, 2007; Hemann and
Narita, 2007). RAS- or BRAF-initiated senescent lesions in vitro and in vivo exhibit
chromatin changes that include the transcriptionally repressive tri-methylation mark at
H3K9 (H3K9me3) and focal enrichment of HP1 proteins for which H3K9me3 provides
a docking site (Bartkova et al., 2006; Braig et al., 2005; Collado et al., 2005; Lachner et
al., 2001; Michaloglou et al., 2005; Narita et al., 2003). Mechanistically,
hypophosphorylated Retinoblastoma (Rb) protein, bound to growth-promoting E2F
transcription factors, may recruit H3K9 methyltransferase activities such as Suv39h1 to
direct heterochromatinization to the vicinity of E2F-responsive promoters, thus
silencing S-phase genes (Narita et al., 2003). Increasing evidence points towards an
oncogene-induced DDR as critical upstream trigger of the senescence program
(Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007). Indeed, Myc and
RAS oncogenes cause DNA damage by inducing reactive oxygen species (ROS) and
generating stalled DNA replication intermediates (Di Micco et al., 2006; Lee et al.,
1999; Reimann et al., 2007; Vafa et al., 2002). However, both prototypic oncogenes
produce very different outcomes – i.e. predominantly cellular senescence following
RAS/BRAF and apoptosis in response to Myc activation – when activated in primary
cells in vitro (Evan et al., 1992; Serrano et al., 1997).
So far, there has been no clear evidence that Myc induction in primary cells may
cause senescence under physiological conditions in vitro or in vivo (Feldser and
Greider, 2007; Grandori et al., 2003; Guney et al., 2006). One cell-autonomous
explanation for Myc’s primarily pro-apoptotic action might be that Myc favors
5apoptosis over arrest by influencing p53-dependent transactivation processes in
response to DNA damage (Seoane et al., 2002).
The purpose of this study was to determine the contribution of cellular senescence
as a tumor-suppressive mechanism in a transgenic mouse model of Myc-driven
lymphomagenesis reminiscent of aggressive B-cell lymphomas in humans. Given the
well-established predominantly apoptotic response to Myc activation in primary cells
in vitro, we specifically aimed to dissect cell-autonomous and non-cell-autonomous
components of Myc-related senescence in vivo.
RESULTS
Suv39h1-Dependent Cellular Senescence Limits Myc-Induced Lymphomagenesis
To determine the role of cellular senescence in Myc-driven tumorigenesis, we
studied the impact of senescence-compromising Suv39h1 loss in Eµ-myc transgenic
mice (Adams et al., 1985; Braig et al., 2005), where genetic disruption of apoptosis
strongly promotes B-cell lymphomagenesis (Egle et al., 2004; Schmitt et al., 2002b;
Strasser et al., 1990). Mice that lacked one or both Suv39h1 alleles developed
lymphomas significantly faster than mice without a targeted defect at the Suv39h1 locus
(P < 0.0001 for either comparison, Figure 1A). Moreover, lymphomas that formed in
Suv39h1+/- female mice invariably lost expression of the X-chromosomally encoded
Suv39h1 transcript, thereby explaining the indistinguishable tumor onset in Suv39h1+/-
and Suv39h1- (i.e. Suv39h1-/y male and Suv39h1-/- female) mice (Figure 1A, insert).
Importantly, the frequency of apoptosis measured as TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling) reactivity, a hallmark of Myc-
driven lymphomas, was virtually identical in Suv39h1-deficient lymphomas when
6compared to control lymphomas (i.e. those that arose in Eµ-myc mice without a targeted
Suv39h1 lesion; Figure 1B). Furthermore, control and Suv39h1-deficient lymphomas
presented with indistinguishable gross pathology, formed at comparable stages of B-cell
development, both expressed Suv39h2 transcripts, and displayed similar near-normal
chromosome counts, unlike the previously reported chromosome-missegregated B-cell
lymphomas that form in the absence of both Suv39h1 and Suvh39h2 alleles in non-
transgenic mice (Peters et al., 2001) (data not shown). Thus, neither compromised
apoptosis nor overt aneuploidy account for the accelerated lymphoma onset in Suv39h1-
deficient Eµ-myc mice.
To directly assess oncogene-induced senescence as a potential component of
delayed lymphoma manifestation, senescence-associated β-galactosidase (SA-β-gal)
activity (Dimri et al., 1995) was analyzed in Suv39h1-deficient and control lymphomas.
Virtually none of the cells in the Suv39h1- lymphoma sections, but an average of about
14% of the control lymphoma cells stained, often in a focal pattern, positive for SA-β-
gal (P < 0.001; Figure 1B and 1C; see Figure S1A and S1B for further evidence that
senescent cells are indeed B-lymphoma cells). Moreover, co-analysis of the
proliferation marker Ki67 or bromodeoxyuridine (BrdU) incorporation, indicating DNA
synthesis, with SA-β-gal or H3K9me3 staining confirmed the growth-arrested nature of
SA-β-gal- or H3K9me3-positive cells (Figure 1D). Immunoblot analyses of bulk lymph
node lysates indicated no differences in the expression levels of Myc and the cell-cycle
inhibitor p21CIP1 between control and Suv39h1- lymphomas, while significant amounts
of hypophosphorylated/G1-phase Rb and of H3K9me3 were only found in control
lymphomas, which also displayed slightly reduced levels of the CDK4/6 inhibitor
p16INK4a and the E2F target Cyclin A (Figure 1E). Other histone modifications such as
H3K4me3, acetylated H3K9, H3K27me3, or H4K20me3 appeared globally unaffected
by Suv39h1 status (data not shown), underscoring the specific role of the Suv39h1-
mediated H3K9me3 mark in the senescence process. Moreover, spleen samples derived
7from young, lymphoma-free Eµ-myc mice (termed ‘pre-neoplastic’, albeit consisting of
Myc-overexpressing normal B-cells) as compared to spleen sections from non-
transgenic mice exhibited signs of cellular senescence in a strictly Myc- and Suv39h1-
dependent fashion, indicating that oncogene-related senescence may delay
tumorigenesis already at a pre-malignant state (Figure S1C). Thus, aggressive Myc-
driven lymphomas develop and manifest with a significant fraction of cells that lack any
proliferative activity and display marks of cellular senescence.
All Myc-lymphomas developing in Suv39h1+/-;p53+/- or S u v 3 9 h 1-;p53+/-
backgrounds selected against the remaining p53 wild-type allele (12/12 cases tested
“p53-null”; Figure 1F), as known from lymphomas forming in Eµ-myc;p53+/- mice
(Schmitt et al., 1999), and, thus, against p53-dependent apoptosis. Suv39h1 RNA
expression was mostly retained in Suv39h1+/-;p53+/--derived lymphomas (7/9 cases
tested; Figure 1F), indicating that p53 loss co-ablates an apoptosis-independent tumor-
suppressive function otherwise governed by Suv39h1. Accordingly, additional
inactivation of Suv39h1 produced no further acceleration of Eµ-myc lymphomagenesis
in a p 5 3+/- background (data not shown). Notably, and different from p53-null
lymphomas, DDR-defective ATM-/- lymphomas displayed only a partial reduction of the
senescent fraction at manifestation (Figure 1G and Figure S1D, showing, in addition,
control lymphoma-comparable senescence in p16INK4a-deficient INK4a-/- and p21CIP1-
deficient CIP1-/- lymphomas, but compromised senescence in ARF-/- lymphomas).
Taken together, Myc-induced senescence presents in vivo as a p53-, Suv39h1-, and
partly ATM-dependent program that complements apoptosis as an anti-oncogenic
safeguard mechanism in Eµ-myc lymphomagenesis.
8Activated Myc Promotes ATM/p53-Dependent Senescence
Myc activation is known to produce marks of DNA damage in vivo (Reimann et
al., 2007), at least in part via ROS, which may link Myc via a DDR to Suv39h1-
dependent senescence. Notably, Suv39h1 had no impact on γ-H2AX-marked DNA
lesions and the DDR signature in pre-neoplastic Eµ-myc transgenic B-cells, or in
lymphoma cells exposed to γ-irradiation (Figure S2A-C). However, in contrast to wild-
type B-cells, primary B-cells lacking the DDR mediators ATM or p53 largely failed –
like Suv39h1-deficient B-cells – to senesce in response to acute Myc overexpression
in vitro (Figure 2A). If senescence detected in control lymphomas in situ is initiated via
a Myc-evoked DDR, then genetic or pharmacological interference with the DDR should
impact on the senescence response. Comparable to the ATM-/- scenario (Figure 1G),
exposure of Eµ-myc transgenic mice to the ROS scavenger N-acetyl-cysteine (NAC) or
to the ATM/ATR inhibitor caffeine that both blunt an oncogene-evoked DDR in vivo
(Bartkova et al., 2006; Reimann et al., 2007) resulted in a profound, albeit only partial
reduction of senescent lymphoma cells in situ (Figure S2D-F, also showing that ROS
levels are Myc- but not Suv39h1-dependent).
To directly address the cell-autonomous potential of Myc to drive senescence, we
tested whether a conditional p53 moiety would suffice to convert constitutive Myc
signaling into a robust senescence response in apoptosis-incapable cells. To this end, we
employed Eµ-myc mice carrying a 4-OH-tamoxifen (4-OHT)-inducible p53ERTAM
knock-in allele, encoding a p53-estrogen receptor fusion protein that is inactive in the
absence of 4-OHT (Martins et al., 2006). Expectedly, Eµ-myc;p53ERTAM/+ lymphomas
that arose in the absence of 4-OHT typically selected against the remaining p53 wild-
type allele (termed p53ERTAM/(-); 5/5 cases tested [data not shown and (Martins et al.,
2006)]), thereby generating p53-null lymphomas in which p53 activity is restorable
upon provision of 4-OHT (Figure S2G). Constitutively Myc-expressing and bcl2-
9transduced (and, thus, apoptosis-protected) lymphoma cells quantitatively entered
senescence following exposure to 4-OHT in vitro, while non-transgenic, Bcl2-protected
p53ERTAM-expressing B-cells lacked such a response (Figure 2B). Similarly,
senescence was strongly induced when mice harboring Eµ-myc;p53ERTAM/(-)/bcl2
lymphomas were exposed to tamoxifen in vivo (Figure 2C). Importantly,
pharmacological scavenging of ROS or ablation of the DDR attenuated, and, when
combined, almost completely blocked the senescence induction of Eµ-myc;p53ERTAM/(-
)/bcl2 lymphoma cells in response to 4-OHT in vitro (Figure 2D). Thus, acute
overexpression of Myc in primary cells or p53 reactivation in the presence of
constitutive Myc signaling unmasks the cell-autonomous, DDR-mediated pro-senescent
capability of Myc.
TGF-β Induces Senescence of Myc-Driven Lymphoma Cells
Because neither ATM deficiency nor pharmacological DDR ablation was
sufficient to fully abrogate senescence of Myc-driven lymphoma cells in vivo, we aimed
to identify an additional stimulus that may complement oncogene-induced DDR
signaling in vivo. Genome-wide transcriptional profiling of whole lymph node RNA
preparations from Suv39h1-proficient vs. Suv39h1-deficient Eµ-myc lymphomas
identified TGF-β-induced gene (Tgfbi; also known as Big-h3, β-ig H3, or
keratoepithelin) as the most strongly differentially upregulated transcript. Tgfbi, a TGF-
β target, was expressed 3.9-fold higher in Suv39h1- lymphomas, and encodes a secreted
protein with cytostatic potential that was previously linked to cellular senescence
(Dokmanovic et al., 2002) (see “Experimental Procedures” section for details and the
confirmatory quantitative RT-PCR [RQ-PCR] analysis in Figure S3A). We found TGF-
β1, known to induce cellular senescence in fibroblasts (Lin et al., 2004), to be detectable
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in a multi-focal pattern in lymphoma sections reminiscent of the distribution of SA-β-
gal-positive cells in control lymphomas (Figure 3A, compare to Figure 1B).
Importantly, co-staining for the proliferation marker Ki67 unveiled that in areas with
abundant TGF-β1 significantly less control cells were Ki67-positive when compared to
Suv39h1- lymphomas (Figure 3A). Thus, TGF-β correlates with a cytostatic response
selectively detectable in control lymphomas, and high Tgfbi levels in Suv39h1- cells are
suggestive for a downstream defect in a TGF-β-inducible senescence program.
We sought to directly test the potential of exogenous TGF-β1 to induce cellular
senescence in a Suv39h1-dependent fashion in Myc-driven lymphoma cells that were
stably bcl2-transduced to block apoptosis. TGF-β1 countered proliferation in a dose-
dependent manner and led to a complete growth arrest with features of cellular
senescence, i.e. SA-β-gal activity and H3K9me3 expression, in control, but not in
Suv39h1- lymphoma cells whose growth behavior remained largely unaffected by TGF-
β1 treatment (Figure 3B). Lack of a cytostatic response in Suv39h1- cells was not due to
a primary defect in TGF-β receptor signaling, since lymphoma cells of both genotypes
exhibited phosphorylation of the intracellular TGF-β1 mediators Smad2 and Smad3
following TGF-β1 treatment in vitro (Figure S3B). In line with the transcriptionally
repressive H3K9me3 mark selectively induced in control lymphomas (Figure 3B), TGF-
β1-treated control lymphomas displayed reduced transcript levels of numerous E2F
target genes, including MCM7 or Cyclin A by microarray analysis, as well as increased
levels of transcripts that encode for components of the heterochromatinization
machinery such as DNA methyltransferase 3B or HP1β (Figure S3C, and Figure 3C for
Cyclin A protein expression). The mechanism by which TGF-β utilizes Suv39h1,
presumably in conjunction with Rb/E2F complexes (Laiho et al., 1990; Schwarz et al.,
1995; Spender and Inman, 2009), to induce senescence appears to be indirect, since we
were unable to detect a physical interaction between Suv39h1 and Smad proteins
(Figure S3D). TGF-β1 was incapable of inducing p15INK4b or p21CIP1 mRNA and
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protein expression in lymphomas independent of their Suv39h1 status, probably because
constitutive Myc expression firmly represses these promoters via Miz-1 (Seoane et al.,
2002; Spender and Inman, 2009) (Figure S3E, and transcriptional levels by RQ-PCR,
data not shown). Unlike γ-irradiation, TGF-β1 treatment of lymphoid cells failed to
produce DNA lesions (Figure S3F and S3G), and was not accompanied by elevated
ROS levels either (data not shown). Of note, H2O2-induced DNA damage, at levels
comparable to DNA damage evoked by oncogenic Myc, synergized with TGF-β to
promote cellular senescence (Figure S3G, compare to γ-H2AX foci in Figure S2A), as
seen for Myc induction and TGF-β treatment in MEFs (Figure S3H). Accordingly,
DDR-defective ATM-/- lymphomas senesced in response to TGF-β1 as control (or,
likewise, p16INK4a- or p21CIP1-deficient) lymphomas did, while p53-null lymphomas
were expectedly refractory (Cordenonsi et al., 2003) (Figure 3D). Hence, TGF-β
promotes cellular senescence without damaging DNA, but cooperatively with
oncogene-related DDR signaling in a Myc-primed and p53/Suv39h1-dependent fashion.
Next, we aimed to identify the cellular source of the considerable amounts of
TGF-β detectable in Eµ-myc lymphoma tissues. Importantly, lymphoma cells did not
secrete TGF-β1 above culture medium background levels (Figure S3I). However,
freshly isolated lymphoma cells exhibited Smad3 phosphorylation (Smad3-P), a mark of
activated TGF-β signaling, while Smad3-P was undetectable in freshly isolated pre-
neoplastic Eµ-myc transgenic B-cells (Figure S3J; see also Figure S1C). Likewise, no
Smad3-P signal was found in non-transgenic B-cells following transduction with a Myc
expression construct, indicating that Myc per se is incapable of driving TGF-β
expression. Notably, the recently observed link between oncogene-induced senescence
and a senescence-reinforcing pro-inflammatory secretory phenotype, termed ‘SASP’
(Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008),
raised the questions whether TGF-β1 might be a component or a regulator of the SASP-
related cytokines. However, RQ-PCR analysis of a panel of SASP candidates in Myc-
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lymphomas of various genotypes exposed to senescence-inducing H2O2 or TGF-β1
unveiled substantial SASP induction only in senescence-capable control lymphomas
following exposure to H2O2 but not to TGF-β1. Moreover, TGF-β1 itself does not
belong to the SASP signature of lymphoma cells, which is different from fibroblasts
that expressed increased amounts of TGF-β1 upon γ-irradiation or H2O2 (Figure S3K-
M). In essence, neither proliferating nor senescent lymphoma cells secrete significant
amounts of TGF-β, implying that TGF-β might be provided by non-neoplastic bystander
cells.
Apoptotic Lymphoma Cells Activate Macrophages to Secrete Pro-Senescent TGF-
β1
We considered lymphoma-infiltrating and -activated macrophages to serve as a
non-cell-autonomous source of TGF-β1 in vivo, since macrophages reportedly secrete
TGF-β1 upon phosphatidylserine (PS)-dependent ingestion of apoptotic cells (Huynh et
al., 2002; Savill and Fadok, 2000), which are typically found at significant frequencies
in Myc-driven lymphomas (Figure 1B, and Figure S4A for the phenotypic
characterization of lymphoma-infiltrating macrophages). Indeed, co-culture of
macrophages with PS-positive apoptotic, but not with PS-negative proliferating
lymphoma cells resulted in increased TGF-β1 secretion, as alternatively observed upon
stimulation of macrophages with PMA (phorbol 12-myristate 13-acetate; Figure 4A and
Figure S4B). Consistently, lymphomas harboring a robust Bcl2-mediated apoptotic
block (control/bcl2; see also ref. (Schmitt et al., 2002b)) presented with a much lower
frequency of both infiltrating macrophages and senescent cells in vivo (Figure 4B and
Figure S4C, see also Figure 1G and Figure S1D for a correlation between senescent
cells and infiltrating macrophages in various lymphoma genotypes). The nearly
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complete absence of senescent control;bcl2 lymphoma cells in vivo despite their
in vitro-susceptibility to TGF-β-mediated senescence (Figure 3B) underscores the
importance of non-cell-autonomous events such as attraction of macrophages (Lauber et
al., 2003) and their subsequent activation by apoptotic lymphoma cells to secrete TGF-
β1.
To further elucidate the pro-senescent role of activated macrophages in vivo, we
adoptively transferred PMA-stimulated Ana-1 macrophages into mice harboring Myc-
driven lymphomas. GFP-tagged Ana-1 cells homed to lymphoma sites, and their
presence correlated with enhanced TGF-β1 pathway activation (i.e. Smad3-P),
induction of the TGF-β target and senescence indicator plasminogen activator inhibitor-
1 (PAI-1), and, most notably, with a substantial increment of senescent lymphoma cells
(Figure 4C, and Figure S4D and S4E). Conversely, systemic depletion of macrophages
by repetitive provision of liposome-encapsulated clodronate (Aichele et al., 2003)
significantly lowered the number of lymphoma-infiltrating macrophages, Smad3
activation (i.e. Smad3-P), and, most importantly, lymphoma cell senescence (Figure 4D,
and Figure S4F and S4G; for effects of pharmacological inhibition of TGF-β production
see Figure S4H-J).
To confirm the impact of TGF-β on senescence induction in vivo, we sought to
locally block its action by expressing a soluble, secretable TGF-β1-neutralizing TGF-β
type II receptor extracellular domain (TβR-II-ED), thereby restricting TGF-β inhibition
to the vicinity of TβR-II-ED-expressing cells (Thomas and Massague, 2005).
Importantly, transplantation of Eµ-myc transgenic hematopoietic stem cells stably
transduced with TβR-II-ED into lethally irradiated recipient mice resulted in a
profoundly accelerated onset of lymphomas (P < 0.0001); these lymphomas virtually
lacked Smad3 phosphorylation and displayed, despite unaffected macrophage
frequencies, much less senescent cells when compared to a mock-infected cohort
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(Figure 4E and 4F and Figure S4K-M). Tumor latency remained unchanged when the
TβR-II-ED moiety was tested in Suv39h1-deficient hematopoietic stem cells, indicating
that TGF-β-mediated apoptosis has no significant tumor-delaying impact in this model
(data not shown). Furthermore, when matched pairs of primary lymphomas were
propagated in immunocompetent recipients, TβR-II-ED-expressing lymphomas always
formed with lower senescence frequencies than the corresponding empty vector samples
(Figure 4G). Thus, selective ablation of TGF-β  action reduces lymphoma cell
senescence in tumor development and in otherwise genetically identical lymphoma
aliquots during tumor expansion in vivo. Importantly, these results, like the sharply
reduced senescence frequency in Bcl2-protected lymphomas in vivo (Figure 4B), clarify
that the non-cell-autonomous induction of senescence is quantitatively substantially
more relevant than the cell-autonomous signaling cascade into senescence (as addressed
in Figure 2).
Ultimately, we aimed to dissect the sequential process of lymphoma cell
apoptosis-induced macrophage-derived TGF-β action on lymphoma cell senescence in a
single in vitro experiment. To this end, we co-incubated Bcl2-protected lymphoma cells
with macrophages, which were activated by exposure to apoptotic lymphoma cells
beforehand, with or without a pharmacological TGF-β receptor type I inhibitor (TGFR-
I). Indeed, only apoptotic body-activated macrophages produced a more than 3-fold
increase of SA-β-gal-positive lymphoma cells that was largely abolished in the presence
of the TGFR-I (Figure 4H and Figure S4N). Therefore, TGF-β secreted by macrophages
upon their activation by apoptotic lymphoma cells indeed acts as a critical stroma-
derived inducer of lymphoma cell senescence.
To test whether the proposed, mouse model-deduced mechanism of non-cell-
autonomous senescence induction may apply to human aggressive B-cell lymphomas as
well, we analyzed its central components in a panel of 30 diffuse large B-cell lymphoma
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samples. The panel was sub-divided based on Ki67 immunoreactivity into a very high
proliferation (Ki67hi; ≥ 80% Ki67-positive cells) and a lower proliferation (Ki67lo;
< 80% Ki67-positive cells) group. Indeed, Ki67lo samples exhibited a significantly
higher frequency of H3K9me3-positive cells, indicative of cellular senescence in
paraffin-embedded sections that cannot be examined for enzymatic SA-β-gal activity
(Figure 5A and 5B). Importantly, the Ki67lo group also presented with a higher fraction
of apoptotic cells, more lymphoma-infiltrating macrophages, and a stronger reactivity
for the TGF-β signaling mediator Smad3-P (Figure 5B). Thus, these data strongly
suggest that environmentally co-controlled tumor cell senescence plays an important
growth-restraining role in human aggressive B-cell lymphomas as well.
DISCUSSION
Our data establish a model of senescence induction in an oncogenic context where
the primary cellular response to the driving oncogene is overt apoptosis, not senescence.
Elegant work elucidating signaling cascades involved in RAS-, BRAF-, or MEK-type
oncogene-induced senescence demonstrated that an oncogene-evoked DDR (Bartkova
et al., 2006; Di Micco et al., 2006; Mallette et al., 2007), a global negative feedback
response attenuating RAS effector signaling (Courtois-Cox et al., 2006), and, most
recently, pro-inflammatory cytokines acting as reinforcing networks (Acosta et al.,
2008; Coppe et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008) contribute to the
senescence phenotype. However, all of these studies view senescence as a cell-
autonomous phenomenon in which, if at all, cellular interactions or secreted factors
promote the senescent arrest in a homotypic self-amplifying way. We report here an
oncogene-initiated but non-cell-autonomous route into senescence. This process
depends on the activation of TGF-β1-secreting non-neoplastic cells as a critical
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intermediate step, linking Myc-provoked cell-autonomous apoptosis to the subsequent
senescence induction of a significant proportion of the remaining tumor cells by the
stromal cytokine (Figure 5C). Hence, our data demonstrate that apoptosis and
senescence are not simply two context-dependent choices of cellular stress
responsiveness, but that they can be enforced in an interdependent fashion on the
organismic level. In this regard, disrupted DNA damage signaling may not only
compromise cell-autonomous induction of cellular senescence (Figure 1G, Figure 2D
and Figure S2E and S2F), but might also anticipate impaired macrophage-related
senescence due to reduced primary apoptosis. Importantly, DDR-defective tumor cells
remain susceptible to non-DNA damaging pro-senescent stimuli that might be
therapeutically exploited in the future. Moreover, our data underscore why p53
inactivation – blocking apoptosis, preventing macrophage attraction, and rendering the
cell insensitive to TGF-β-induced senescence – is a particularly efficient way to escape
Myc-related senescence.
We would like to emphasize that 12-20% senescent cells, which were detectable
in control lymphomas at diagnosis, are indeed likely to account for a substantial delay in
tumor formation. These frequencies reflect “snap-shots” of a dynamic process that
involves rapid clearance of senescent cells by the host immune system (J.R.D. and
C.A.S., manuscript in preparation), as recently reported for a mouse model presenting
with senescent liver cancer cells (Xue et al., 2007). The profound impact on overall
tumor growth of relatively small steady-state proportions of cells that exited the cycle is
well established in the apoptosis field and seems to apply to senescent cells in a
comparable way.
Of note, cellular and secreted components that delay tumor manifestation via
senescence as shown here do not necessarily keep operating as tumor constraints during
later steps of cancer progression, as there is ample evidence that both tumor-associated
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macrophages and TGF-β can produce deleterious effects by promoting tumor growth or
by exerting tolerogenic immune effects (Dave et al., 2004; Thomas and Massague,
2005). However, TGF-β1 signaling has just been reported as a component of the
prognostically favorable “stromal-1” signature in human diffuse large B-cell lymphoma
(Lenz et al., 2008), a frequently Myc-activated entity in which we identified here a
subgroup with features highly reminiscent of the presented mechanism of macrophage-
mediated senescence induction that we genetically dissected in the murine Eµ-myc
model of aggressive B-cell lymphoma.
Furthermore, our findings characterize the Rb-related Suv39h1-mediated
H3K9me3/HP1 heterochromatin mark as a rather universal and essential downstream
effector module of the senescence program that is still operational in the presence of
constitutive Myc signaling. This chromatin mark is produced not only by activated
oncogenes or DNA damaging chemotherapy (Braig et al., 2005; Collado et al., 2005;
Michaloglou et al., 2005) but also by the cytostatic action of secretory TGF-β. Given the
anti-cancer relevance of cellular senescence, the now demonstrated inducibility of
senescence by a non-DNA damaging cytokine opens the exciting perspective to utilize
Suv39h1/H3K9me3-enforcing approaches for future cancer therapies.
EXPERIMENTAL PROCEDURES
Lymphoma Analysis and In vivo-Treatments
All animal protocols used in this study were approved by the governmental review
board (Landesamt Berlin), and conform to the respective regulatory standards.
Lymphomas with defined genetic defects were generated by intercrossing Eµ-myc
transgenic mice with mice carrying loss-of-function alleles at the Suv39h1, the p53, the
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INK4a/ARF, the CIP1 or the ATM locus, all in a C57BL/6 background (Adams et al.,
1985; Barlow et al., 1996; Christophorou et al., 2005; Deng et al., 1995; Jacks et al.,
1994; Kamijo et al., 1997; Krimpenfort et al., 2001; Peters et al., 2001). Genotyping of
the offspring by allele-specific genomic PCR, monitoring of lymphoma onset,
preservation of snap-frozen or formalin-fixed lymph node tissue and isolation of viable
lymphoma cells, splenic B-lymphocytes (via magnetic bead selection [B-cell isolation
kit, Miltenyi]), fetal liver cells (FLC), primary peritoneal macrophages (pMP) or mouse
embryo fibroblasts (MEF) were carried out as described (Davies and Gordon, 2005;
Reimann et al., 2007; Schmitt et al., 2002a; Schmitt et al., 2002b). Where indicated, B-
cells were pre-stimulated for 48 hours with 5 µg lipopolysaccharide (LPS)/ml (from
Salmonella enterica; Sigma-Aldrich). Pre-neoplastic cells were obtained from
approximately 30-days-old Eµ-myc transgenic animals devoid of lymph node or spleen
enlargement and with no evidence of leukemia by blood smear analysis. In some
experiments, mice were exposed to specific drug treatments as described in the
Supplemental Experimental Procedures. The use of tumor biopsies primarily obtained
for the initial diagnosis of diffuse large B-cell lymphoma as anonymous samples was
approved by the local ethics commission of Charité - Universitätsmedizin Berlin
(reference EA4/085/07). Detection of apoptotic DNA strand breaks by TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end labeling; Roche) staining in
paraffin-embedded tissue sections and assessment of SA-β-gal activity at pH 5.5 in
cryosections or cytospin preparations of cell suspensions were carried out as described
(Schmitt et al., 2002a; Schmitt et al., 1999). Eµ-myc transgenic FLC as a source of
hematopoietic stem cells were obtained to reconstitute (sub-)lethally (i.e. a single 6 or
10 Gy-dose of total body γ-irradiation) irradiated non-transgenic recipient mice. FLC,
splenic B-lymphocytes, isolated lymphoma cells (typically on irradiated NIH3T3
fibroblasts serving as feeders), macrophages and MEFs were cultured in liquid medium
or semi-solid methylcellulose as described (Schmitt et al., 1999; Schmitt et al., 2000),
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and stably transduced with MSCV-c-Myc-IRES-GFP, MSCV-HA-Suv39h1-puro
(kindly provided as pcDNA3.1-HA-Suv39h1 by A. Leutz), MSCV-bcl2-blasticidine,
MSCV-bcl2-puro, pBabe-c-MycERTAM-puro (a generous gift from M. Eilers) or the
GFP co-encoding retroviruses MSCV-IRES-GFP and MSCV-TβR-II-ED-IRES-GFP
(kindly provided as MSCV-TβR-II-ED-puro by J. Massagué) (Reimann et al., 2007;
Schmitt et al., 1999; Schmitt et al., 2002b); the C57BL/6-derived Ana-1 macrophages
(kindly provided by L. Varesio) were GFP-transduced via nucleofection (nucleofector
kit V, Lonza). In some settings, macrophages were treated in vitro with phorbol 12-
myristate 13-acetate (PMA; Sigma), lisinopril, or adriamycin (Sigma) for the indicated
times and at the indicated concentrations.
Analysis of Growth Parameters, Chromosomal Abnormalities and DNA Damage
In some experiments, lymphoma cells were exposed in vitro to purified human
TGF-β1 (R&D Systems) at 100 or 1000 pM, or were treated with 1 µM 4-hydroxy-
tamoxifen (4-OHT; Sigma-Aldrich) or the equivalent volume of the ethanol-based
solvent, or were incubated with H2O2 (100 µM; Sigma-Aldrich), or were exposed to the
TGF-β R I inhibitor V (SD-208; 500 nM; Calbiochem/Merck) for the indicated times, or
were treated with NAC or caffeine (Sigma-Aldrich) as stated. Viability and cell
numbers were analyzed by trypan blue dye exclusion, cell-cycle parameters by BrdU
and propidium iodide (PI) staining (Schmitt et al., 1999; Schmitt et al., 2002b). For
numeric karyotypic analysis, at least twelve DAPI stained metaphases were counted per
lymphoma sample (Schmitt et al., 2002b). Cytospin preparations of suspension cultures
for subsequent SA-β-gal analyses or immunostainings, quantification of ROS by 2’-7’-
dichlordihydrofluorescein-based flow cytometric analyses, and quantification of DNA
strand breaks in Annexin V-negative cells (Miltenyi) by the Comet assay were carried
out as previously described (Braig et al., 2005; Reimann et al., 2007).
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Gene Expression Analysis
Genome-wide expression analysis was performed on RNA isolated with Trizol
(Invitrogen) from whole lymph nodes derived from individual lymphoma-bearing mice
and from normal spleen as control, or, in a second set of experiments, from short-term
cultured lymphoma cells with and without exposure to 100 pM of human TGF-β1 for 24
hours using a 22.5 K mouse cDNA array. For RT-PCR analyses, RNA extracts were
transcribed into cDNA using SuperScript reverse transcriptase (Invitrogen) and random
hexamers or oligo-dT. Primer sequences and detailed PCR protocols for the detection of
murine ACE, Suv39h1, Suv39h2, TβRII-ED, and TATA box binding protein (TBP; as an
internal control) transcripts as well as for the RQ-PCR analyses of mouse CIP1, CTGF,
CXCL1, CXCL7, CXCL16, GAPDH, GM-CSF, IGFBP6, IGFBP7, IL-1α, IL-6, IL-7,
INK4b, MCP-4, MIP-3α, MMP2, MMP3, Tgfig, TGF-β1, TGF-β2, TGF-β3, and VEGF
transcripts (using commercially available primers; Applied Biosystems) are available
upon request. For every given sample, ∆Ct values were determined as the difference
between the Ct value of a specific transcript and the Ct value of GAPDH, serving as the
housekeeping control mRNA, and relative transcript levels (e.g. treated vs. untreated)
were then produced based on 2(-∆∆Ct) with ∆∆Ct = ∆Cttreated - ∆Ctuntreated.
Immunophenotyping by flow cytometry as well as antigen detection by
immunofluorescence (IF), immunohistochemistry (IHC), immunoblotting (IB), and
immunoprecipitation (IP) was carried out as described (Reimann et al., 2007; Schmitt et
al., 2002a). A summary of the methods and the complete list of antibodies used can be
found in the Supplemental Experimental Procedures. Staining intensities of Smad3-P or
PAI-1 in situ were semi-quantitatively assessed (- vs. +, ++ or +++; converted into
numeric values 0, 1, 2 or 3 to calculate a mean in some experiments [where a value of
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around 0.5 would translate into (+)]). TGF-β1 protein concentrations were also
measured by ELISA (Quantikine, R&D Systems) in HCl-activated cell-free culture
supernatant in accordance with the manufacturer’s protocol.
Statistical Evaluation
Tumor onset data reflecting the latency between birth and first-time palpability of
enlarged lymph nodes were compared using the log-rank (Mantel-Cox) test. Curve
fitting analysis was done by linear regression with R2 as the coefficient of
determination. The unpaired t-test was used to compare means and standard deviations
(SD). All quantifications from staining reactions (e.g. immunostainings, TUNEL or SA-
β-gal assays) were carried out by an independent and blinded second examiner, and
reflect at least three samples with at least 200 events counted (typically in more than
three different tissue areas) each.
Accession Numbers
Details about the cDNA microarray protocols, the specific array design, and the
respective data can be found at http://www.ebi.ac.uk/arrayexpress/ under accession
number E-MEXP-1423 for the first set and E-MEXP-1424 for the second set of
experiments.
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Supplemental data include Supplemental Experimental Procedures, Supplemental
References, and four figures, and can be found with this article online at
http://www.cell.com/cancer-cell/supplemental/xxx.
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FIGURE LEGENDS
Figure 1. Suv39h1-Dependent Senescence Attenuates Myc-Driven
Lymphomagenesis
(A) Latencies to palpable lymphoma manifestation in Eµ-myc transgenic mice (control
lymphoma, n = 93, black), in Eµ-myc;Suv39h1+/- (n = 41, red), and in Eµ-myc;Suv39h1-
mice (n = 31, orange). Insert: Suv39h1 mRNA expression by RT-PCR analysis of short-
term cultured lymphomas derived from Suv39h1+/- mice (n = 4) with a Suv39h1+/+
derived lymphoma for comparison; TBP as an internal control.
(B) Growth-related parameters, i.e. apoptosis by TUNEL reactivity, and senescence by
SA-β-gal staining in lymph node sections obtained at manifestation from Eµ-myc
control or Suv39h1- lymphomas (representative photomicrographs from at least nine
samples per genotype tested).
(C) Percentages of SA-β-gal-positive cells (as in b) in individual control (n = 25) and
Suv39h1- (n = 9) lymphomas. Horizontal lines represent the mean percentage of each
group. Note that low-level SA-β-gal-positive cases in the control group are enriched for
spontaneously p53 mutant or homozygously INK4a/ARF-deleted lymphomas (Schmitt
et al., 1999) (data not shown).
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(D) Percentages of Ki67-positive (red) and BrdU-positive cells (brown; note the
mutually exclusive SA-β-gal-co-staining [blue]) in situ, and quantification of
H3K9me3high/Ki67low cells (arrow-marked gate, representing senescent cells) by flow
cytometry in control and Suv39h1- lymphomas.
(E) Immunoblot analyses of the indicated proteins in individual control (lanes 1-4) and
Suv39h1- (lanes 5-8) lymphoma cell lysates with α-Tubulin as a loading control (arrow
indicates the hypophosphorylated [hypo-P] Rb band representing cells in G1).
(F) Genomic status of the p53 locus by allele-specific PCR (top) and expression status
of Suv39h1 transcripts by RT-PCR (bottom; TBP as an internal control) analyses of
short-term cultured lymphoma cells that were isolated from mice of the indicated
genotypes. Extracts from p53+/- and p53-/- MEFs as controls.
(G) Frequencies of SA-β-gal-positive cells in Eµ-myc lymphoma cryosections of the
indicated genotypes at diagnosis (control and Suv39h1- as in b, at least four cases per
genotype tested).
All numbers indicate the mean percentages of positive cells ± SD; “*” reflects P < 0.05.
All scale bars = 50 µm (identical magnification throughout the panel). See also Figure
S1.
Figure 2. Myc has p53-Dependent Pro-Senescent Potential
(A) Relative fractions of SA-β-gal-positive non-transgenic primary B-cells of the
indicated genotypes 10 days after stable transduction with a Myc construct (≥ 80% of
the cells infected; dead cells [around 40% initial apoptosis] were removed, resulting in
about 5% senescent cells in the wild-type population) as compared to an empty vector.
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(B) Growth parameters (i.e. Ki67, S-phase fraction by BrdU/PI [arrow], and SA-β-gal
frequencies) in bcl2-infected non-transgenic B-cells (left) and Eµ-myc;p53ERTAM/(-)/bcl2
lymphoma lymphomas (right) in which functional p53 is restored in response to 4-OH-
tamoxifen (4-OHT; solvent serving as the negative control) treatment for six days. Scale
bar = 20 µm (identical magnification throughout the panel).
(C) Acute induction of functional p53 by administration of tamoxifen in mice bearing
lymphomas as in (B); stained for BrdU labelling, Ki67 reactivity (H3K9me3:
10.7% ± 3.5 [solvent] vs. 39.0% ± 6.2 [tamoxifen]), apoptosis-indicating cleavage (cl.)
of Caspase 3, and SA-β-gal activity. Scale bar = 50 µm (identical magnification
throughout the panel).
(D) SA-β-gal frequencies in lymphomas as in (B) exposed in vitro for six days to 4-
OHT (or a solvent as negative control) with no additional compound, or 5 mM of the
ATM/ATR inhibitor caffeine (caf), 5 mM of the ROS scavenger N-acetyl-cysteine
(NAC), or both.
At least three cases each in all these experiments; all numbers indicate the mean
percentages of positive cells ± SD; “*” reflects P < 0.05. See also Figure S2.
Figure 3. TGF-β Induces Suv39h1-Dependent Cellular Senescence in Myc-Driven
Lymphomas
(A) Focal TGF-β1 detected by immunostaining (left) and co-staining (right) for TGF-β1
(red) and Ki67 (blue) in control vs. Suv39h1- lymphomas in lymph node sections in situ
(representative photomicrographs). Inserts show TGF-β1-rich areas at higher
magnification, and percentages reflect the fraction Ki67-positive cells within those areas
(n = 3 samples each). Scale bar = 50 µm (identical magnification throughout the panel).
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(B) Growth curve analyses of freshly isolated and stably bcl2-infected control and
Suv39h1- lymphoma cells exposed to the indicated concentrations of TGF-β1 (100 pM
[red], 1000 pM [green]) or left untreated (black); n = 5 each. Inserts show untreated vs.
TGF-β1-exposed (100 pM; day 5) lymphoma cell cytospin preparations assayed for SA-
β-gal (top; 50.0% ± 13.2 [control] vs.  3.3% ± 2.9 [Suv39h1-] for TGF-β1) and
H3K9me3 reactivity (bottom; in red with DAPI as counterstain; 35.4% ± 14.4 [control]
vs. 0.4% ± 0.1 [Suv39h1-] for TGF-β1). Note the comparable proliferative capacities of
Suv39h1-proficient and -deficient lymphoma cells in the absence of TGF-β1 treatment.
Scale bar = 10 µm (identical magnification throughout the panel).
(C) Immunoblot analysis of Cyclin A protein levels (α-Tubulin as a loading control) in
lymphomas as in (B) with or without preceding exposure to TGF-β1 (100 pM for 5
days).
(D) Relative growth of Bcl2-expressing lymphoma cells of the indicated genotypes after
5 days of exposure to TGF-β1 (100 pM) vs. untreated (as in [B]). At least three cases
each.
Error bars denote the SD.; “*” reflects P < 0.05. See also Figure S3.
Figure 4. Environmental TGF-β, As Secreted by Apoptotic Lymphoma Cell-
Activated Macrophages, Accounts For Lymphoma Cell Senescence In Vivo
(A) Relative induction of TGF-β1 protein levels at 48 hours by ELISA in cell culture
supernatants of primary peritoneal macrophages (pMP) alone or after co-culture with
Eµ-myc;p53ERTAM/(-) lymphomas exposed for 20 hours to 4-OHT or solvent (n = 3 each;
relative to the normalized medium-corrected ‘pMP solvent’ value). Note that 4-OHT,
but not solvent, quantitatively produced PS-positive apoptotic lymphoma cells
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(Figure S4B). Relative induction of TGF-β1 secretion at 48 hours by PMA-stimulated
(200 ng/ml) Ana-1 macrophages for comparison (in triplicate).
(B-D) Quantification of macrophage infiltration (Mac) measured by F4/80
immunostaining (numbers indicating average macrophage count per high-power field)
and of senescence (Sen) assessed by SA-β-gal staining (B) in apoptosis-blocked Bcl2-
expressing lymphomas, generated by retroviral bcl2 transfer (or an empty vector as
control) into Eµ-myc transgenic fetal liver cells and their subsequent propagation in
lethally irradiated recipients, at manifestation, (C) following adoptive transfer of PMA-
stimulated Ana-1 macrophages (as in [A]) by intravenous transfer into control
lymphoma bearing mice, and (D) after systemic monocyte/macrophage depletion by
liposome-encapsulated clodronate or empty liposomes for comparison.
(E) Tumor latencies, stratified by lymphoma GFP expression, in lethally irradiated
recipients of Eµ-myc transgenic fetal liver cells stably transduced with the MSCV-TGF-
β receptor type II ecto domain-IRES-GFP (TβR-II-ED/GFP) retrovirus (TβR-II-
ED/GFP-positive, n = 9, green, vs. mock/GFP-negative, n = 11, black).
(F) Quantification of macrophage infiltration and senescence, assessed as in (B-D), in
TβR-II-ED/GFP-expressing vs. mock-infected lymphomas as in (E). Note that around
10-20% of the overall senescence frequency can be attributed to the cell-autonomous
component (see also [B]).
(G) Matched pair quantification of cellular senescence in individual control lymphomas
(n = 6) infected with the TβR-II-ED/GFP or an empty/GFP retrovirus that formed after
sorting and transplantation of GFP-expressing cells.
(H) Senescence frequencies of bcl2-infected control lymphoma cells exposed – in the
presence or absence of the TGF-β receptor type I inhibitor SD-208 (TGFR-I; 500 nM) –
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to pMP that were either native or co-cultivated with Eµ-myc;p53ERTAM/(-) lymphomas
plus solvent or 4-OHT for 48 hours.
All experiments in this figure represent at least three independent samples each; all
numbers indicate mean values ± SD; “*” reflects P < 0.05; “n.s.” not significant. See
also Figure S4.
Figure 5. Human Diffuse Large B-Cell Lymphomas (DLBCL) Display Features
Consistent with the Model of Non-Cell-Autonomous TGF-β-Mediated Cellular
Senescence
(A) Two DLBCL cases reflecting a highly (Ki67hi; samples with ≥ 80% Ki67-positive
cells) and a less intensely proliferating (Ki67lo; samples with < 80% Ki67-positive cells)
subgroup also stained for apoptosis (cleaved Caspase 3), macrophage infiltration
(CD68), TGF-β pathway activation (i.e. Smad3-P), and cellular senescence (i.e.
H3K9me3 as a surrogate marker). Representative photomicrographs of a total of 30
cases analyzed. Scale bar = 100 µm (identical magnification throughout the panel).
(B) Quantitative assessment of cleaved (cl.) Caspase 3, CD68, Smad3-P, and H3K9me3
in the Ki67 low vs. high groups (Ki67lo, n = 19, Ki67 reactivity 68.7% ± 6.6 vs. Ki67hi,
n = 11, 88.9% ± 5.7; P < 0.001). All comparisons are highly statistically significant (i.e.
P < 0.001), except a trend (P = 0.07) for cl. Caspase 3. All numbers indicate mean
values ± SD; “*” reflects P < 0.05. Notably, no clear association of the Ki67 status with
the germinal center (GC) B-cell-of-origin status (GCB vs. non-GCB by immunostaining
(Hans et al., 2004), data not shown) was observed.
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(C) Model of oncogene-initiated cell-autonomous and non-cell-autonomous cellular
senescence in aggressive B-cell lymphomas, as concluded from Eµ-myc mouse
lymphoma data.
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3
4 Figure S1. Analysis of Growth-Related Parameters in Non-Transgenic, Pre-neoplastic
and Malignant Lymphoid Tissues of Mice with Defined Genetic Lesions. Related to
Figure 1
 (A) Immunofluorescence analyses of H3K9me3- and HP1γ-expressing (insert; control
14.1% ± 5.0; Suv39h1- 3.1% ± 1.3) cells, recapitulating the frequency of SA-β-gal-positive
cells found in lymphoma sections in situ (left; compare to Figure 1B and 1C). Co-staining of
the B-cell marker B220 (red) and H3K9me3 (brown) in lymph node sections of control and
Suv39h1- lymphoma to verify the B-cell origin of the H3K9me3-reactive cells (right;
representative photomicrographs of at least three cases each). Scale bar = 20 µm (identical
magnification throughout the panel).
5(B) SA-β-gal frequencies in lymphomas that formed upon propagation of Eµ-myc Suv39h1+/+
fetal liver cells in sublethally irradiated non-transgenic Suv39h1- recipients, or, vice versa, of
Eµ-myc Suv39h1- fetal liver cells (FLC) transplanted into non-transgenic Suv39h1+/+ (i.e.
wild-type) mice, as well as SA-β-gal analyses of Myc-lymphomas of the indicated genotypes
transplanted at manifestation into either Suv39h1-proficient or -deficient recipient mice,
supporting the view that lymphoma cells but not non-neoplastic bystanders comprise the
fraction of SA-β-gal-positive cells. All numbers indicate the mean percentages of positive
cells ± SD, measured in at least three independent samples; “*” reflects P < 0.05; “n.s.” not
significant.
(C) Representative photomicrographs of spleen samples obtained from Suv39h1+/+ and
Suv39h1- non-transgenic and Eµ-m y c transgenic pre-neoplastic mice stained with
hematoxylin/eosin (H/E) or assessed for the indicated markers in situ. Note the massive Myc-
dependent but Suv39h1-independent peri-follicular proliferation and expansion of B-cells (by
B220 and Ki67 immunostaining, and detection of BrdU incorporation) accompanied by a
rather modest increase of apoptotic cells (as evidenced by cleaved Caspase 3) at this stage.
Compared to the non-transgenic specimens, no Myc-related, additional infiltration of
macrophages is observed above the substantial presence of red pulp-associated string
macrophages (detected by F4/80 staining), which appear not to be activated to secrete
increased amounts of TGF-β as there is no difference in the sparse pattern of Smad3-P-
positive cells between non-transgenic and Eµ-myc pre-neoplastic samples (also compare to
Figure S3J, demonstrating no detectable Smad3-P in bulk lysates of freshly isolated and
immunobead-selected non-transgenic and pre-neoplastic B-cells by immunoblot analysis,
while manifest lymphoma cells presented with intense Smad3-P signals). Importantly, a
significant increase of SA-β-gal-positive peri-follicular cells became evident in Suv39h1+/+
pre-neoplastic samples as compared to their rarity in the non-transgenic spleen, whereas
Suv39h1- samples remained virtually negative for senescent cells independent of their Myc
status. Scale bar = 200 µm (identical magnification throughout the panel).
6(D) H/E staining and immunohistochemical analysis of markers reflecting proliferation
(Ki67), cellular senescence (H3K9me3; compare to Figure 1G), and macrophage infiltration
(F4/80) as well as TGF-β1 secretion in Eµ-myc transgenic lymphomas with defined genetic
lesions. Note the virtual absence of H3K9me3 reactivity in the most uniformly Ki67-positive
Suv39h1-, ARF-/- and p53-null genotypes, with very low contents of lymphoma-infiltrating
macrophages and low amounts of TGF-β1 in situ restricted to the apoptosis-compromised
(Schmitt et al., 2002; Schmitt et al., 1999) ARF- and p53-deficient lymphoma genotypes,
while no difference was found regarding the macrophage frequencies and TGF-β1 (see
Figure 3A and Figure S3J) between control and Suv39h1- lymphomas. ATM-/- lymphomas,
known to form with less apoptotic cells when compared to control lymphomas (Reimann et
al., 2007), exhibit a slightly reduced degree of macrophage infiltration. Photomicrographs
reflect representative samples of at least three individual lymphomas per genotype. Scale bar
= 100 µm (identical magnification throughout the panel).
7
8Figure S2. The Oncogene-Evoked DDR and ROS Cell-Autonomously Drive Induction of
Cellular Senescence. Related to Figure 2
(A) Quantification of γ-H2AX foci per cell by immunofluorescence in immunobead-selected
non-transgenic (non-tg.) vs. constitutively Myc-expressing pre-neoplastic (myc pre.) splenic
Suv39h1+/+ and Suv39h1- B-cell preparations (n = 3 individual preparations each; numbers
indicate the mean counts ± SD). Scale bar = 5 µm (identical magnification throughout the
panel).
(B) Immunoblot analyses of the indicated DDR components in lysates of B-cell preparations
as in (A); α-Tubulin as a loading control. (C) Immunoblot analyses of the indicated DDR
components in control vs. Suv39h1- lymphoma cells (n = 3 individual samples each) with or
without preceding γ-irradiation (2 hours after 4 Gy); α-Tubulin as a loading control.
(D) 2’-7’-Dichlorodihydrofluorescein diacetate-based flow cytometric analysis of cellular
ROS levels in freshly isolated and immunobead-selected B-cells demonstrate that no
significant differences exist between Suv39h1-proficient and -deficient cells of the respective
stages (n = 3 individual preparations each). All numbers indicate mean values ± SD.
 (E) Cellular ROS levels (left; measured as in [D] by flow cytometry; representative
photomicrographs of cytospin preparations by fluorescence microscopy) and corresponding
SA-β-gal staining (right) of control lymphoma sections at manifestation after life-long
exposure to N-acetyl-cysteine (+ NAC) or mock treatment (– NAC). Numbers indicate mean
cellular ROS levels (insert: ROS level in untreated Suv39h1- lymphoma cells; 14.3 ± 4.2) or
percentage of positive cells (SA-β-gal) ± SD obtained from at least five samples each. Scale
bar = 20 µm (identical magnification throughout the panel).
(F) Quantification of p53-P-Ser18 by immunofluorescence (left) and corresponding SA-β-gal
staining (right) in control lymphomas isolated at manifestation after life-long exposure to the
ATM/ATR inhibitor caffeine or mock treatment. Numbers indicate the percentage of cells
with positive nuclear staining (with respect to p53-P-Ser18) ± SD (representative
9photomicrographs from at least five samples each); “*” reflects P < 0.05. Scale bar = 20 µm
(identical magnification throughout the panel).
(G) Biochemical characteristics of Eµ-myc transgenic lymphomas carrying an inducible p53
allele: immunoblot analyses of the p53 targets Puma and p21CIP1 in lysates of three Eµ-
myc;p53ERTAM/(-) lymphoma samples with and without exposure to 4-OHT (which also
resulted in p53ER shuttling to the nucleus as confirmed by anti-ER immunofluorescence [data
not shown]). Notably, p53 restoration is sufficient to drive p21CIP1 expression despite
constitutive Myc expression (as seen in response to DNA damage (Schmitt et al., 1999)),
although Myc has been shown to selectively inhibit p53 from activating CIP1 translation in
other settings (Seoane et al., 2002).
10
11
12
Figure S3. TGF-β Signaling in Myc-Driven Lymphomas. Related to Figure 3
(A) Relative abundance of Tgfbi transcripts (as identified by microarray expression analysis;
see “Experimental Procedures” section for details) by quantitative RT-PCR (RQ-PCR)
analysis in freshly isolated immunobead-selected B-cell samples of Suv39h1- lymphomas
compared to normalized levels in control lymphomas (n = 3 individual lymphomas each).
(B) Expression of phosphorylated Smad2 protein (Smad2-P) by immunoblot analysis (top)
and of Smad3-P by immunocytochemical analysis (bottom) in two samples of control and
Suv39h1- lymphoma cells treated with 100 pM TGF-β1 for 24 hours or left untreated; α-
Tubulin as a loading control. Scale bar = 50 µm (identical magnification throughout the
panel).
(C) Relative transcript abundances (visualized as heat-map [red: down, green: up] and log2
ratio [Suv39h1-/control]) of selected differentially regulated genes in control and Suv39h1-
lymphomas exposed to 100 pM TGF-β1 for 24 hours in vitro (n = 4 each).
(D) No detectable interaction of Suv39h1 with Smad2-P or Smad4 in lysates from TGF-β1-
treated (100 pM for 6 hours) or untreated mouse embryo fibroblasts (MEF) stably expressing
hemagglutinin (HA)-tagged Suv39h1 by immunoprecipitation with antibodies against IgG or
the HA-tag followed by immunoblot analysis for the respective Smad proteins (top);
confirmation of HA-Suv39h1 protein expression in infected MEF (bottom); α-Tubulin as a
loading control.
(E) p15INK4b and p21CIP1 expression by immunoblot analysis in control and Suv39h1-
lymphomas exposed to 100 pM TGF-β1 for 24 hours in vitro or left untreated. α-Tubulin as a
loading control. Of note, p53- and TGF-β-responsive elements and Miz-1 binding sites map to
different regions of the CIP1 promoter (Seoane et al., 2002), which may explain, at least in
part, the different p21CIP1 responses to TGF-β treatment as compared to p53 reactivation
(Figure S2G) in Myc-driven lymphomas.
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(F) Marks of DNA damage following TGF-β1 treatment (100 pM for 20 hours) vs. untreated
(ut) by quantification of Comet mean tail moments and of γ-H2AX foci in Annexin V-
negative control and Suv39h1- lymphomas; samples two hours after γ-irradiation (10 Gy for
Comet, 4 Gy for γ-H2AX foci) as internal control (n = 3 samples each). Scale bar = 5 µm
(identical magnification throughout the panel).
(G) Marks of DNA damage as measured by γ-H2AX foci/cell (left) and cellular senescence as
analyzed by SA-β-gal staining (right) in LPS-stimulated, apoptosis-blocked Eµ-bcl2
transgenic (but not Eµ-myc transgenic) B-lymphocytes (Strasser et al., 1990) at day 7 after
treatments with either H202 (100 µM), TGF-β1 (100 pM) or both or no treatment (n  = 3
individual lymphocyte preparations each).
(H) Cellular senescence as analyzed by SA-β-gal staining in MycERTAM MEFs – in which
Myc is inactive in the absence of 4-OHT – with (right) or without (left) a Bcl2-mediated
apoptotic block at day 7 after treatments with either 4-OHT (1 µM) or TGF-β1 (100 pM) or
both or no treatment/solvent only (n = 3 individual MEF preparations each). Note that TGF-β
is capable of inducing senescence in the absence of activated Myc.
(I) Absolute TGF-β1 concentrations by ELISA in cell culture media/supernatants of the
indicated scenarios; unstimulated primary peritoneal macrophages (pMP) for comparison (n =
3 each). Of note, additional RQ-PCR analyses of short-term cultured lymphoma cells found
transcript levels of TGF-β2 and TGF-β3 at even lower levels than TGF-β1-encoding
transcripts in both control and Suv39h1- genotypes (data not shown), indicating that none of
the TGF-β forms is expressed in Eµ-myc transgenic B-cell lymphoma cells.
(J) Myc, ARF and Smad3-P protein expression (with α-Tubulin as a loading control) in
lysates from non-transgenic B-cells infected with a Myc-encoding, an empty (vec.) or no
(mock) retrovirus as compared to freshly isolated and B-cell-immunobead-selected Eµ-myc
transgenic pre-neoplastic or manifest control lymphoma cells, respectively. Note that ARF
expression is expectedly tightly related to Myc expression, but constitutively Myc-(over)-
expressing non-transgenic or pre-neoplastic B-cells do not display TGF-β pathway activation,
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as reflected by lack of Smad3-P expression. Given the observation that some Eµ-myc
transgenic B-cells already exhibited signs of cellular senescence at the pre-neoplastic state
without displaying a parallel increment of Smad3-P-positive cells (Figure S1C), it seems
conceivable that early SA-β-gal-positive lesions rather senesced due to a cell-autonomous
Myc-evoked DDR.
(K) Senescence induction in lymphoma cells of the indicated genotypes exposed to an H2O2
(100 µM) pulse treatment for two hours and stained for SA-β-gal activity on day 5; shown are
representative photomicrographs. Scale bar = 20 µm (identical magnification throughout the
panel).
(L) Relative abundances of the indicated cytokine transcripts measured by RQ-PCR in bcl2-
infected lymphomas of various genotypes at day 5 following pulse treatments with either
H2O2 (100 µM for two hours as in [K]) or TGF-β1 (100 pM for six hours) as compared to
untreated samples of the same genotype (n = 5 for control and Suv39h1-; n = 3 for p53-null).
Cytokine listing is ranked by induction levels upon H2O2 in control;bcl2 lymphoma cells.
(M) Relative changes of TGF-β1 concentrations by ELISA in cell culture supernatants of
NIH3T3 fibroblasts and bcl2-infected lymphoma cells of the indicated genotypes five days
after senescence-inducing doses (6 Gy) of γ-irradiation vs. no treatment (n = 3 individual
lymphoma preparations each; NIH3T3 fibroblasts in triplicate; background levels subtracted).
Note that only fibroblasts but not lymphoma cells (including senescence-capable control
lymphoma cells) exhibited a significant increase of TGF-β1 secretion following therapy
(similar data were obtained for H2O2 treatment; data not shown).
All numbers in this Figure indicate mean values ± SD; “*” reflects P < 0.05.
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Figure S4. Characterization of The Lymphoma Cell Apoptosis/ Lymphoma-Infiltrating
Macrophages/ TGF-β Secretion Cascade Into Senescence. Related to Figure 4
 (A) Immunophenotyping of whole lymph node cell isolates from control vs. Suv39h1-
lymphoma samples by flow cytometry assigns lymphoma-infiltrating macrophages
17
independent of the lymphoma genotype to the  “M2 type”, i.e. CD206-positive, tumor-
associated macrophages that are known to serve as a source of TGF-β1 (Mantovani et al.,
2002) (n = 5 individual lymphoma preparations each; presented is the fraction of CD206-
positive cells within the F4/80-positive macrophage population).
(B) Apoptosis-related phosphatidylserine externalization detected by Annexin V flow
cytometric staining of Eµ-myc;p53ERTAM/(-) lymphomas exposed to solvent or 4-OHT (1 µM
for 24 hours; representative plot of n = 3 individual lymphomas). Note the quantitative
apoptosis induction 24 hours after exposure to 4-OHT, as compared to an increase of around
6% apoptotic cells detectable in non-transgenic p53ERTAM/(-) cells (data not shown).
(C) Senescence reflected by SA-β-gal staining and assessment of macrophage infiltration by
F4/80 immunostaining in apoptosis-blocked Bcl2-expressing lymphomas, generated by
retroviral bcl2 transfer (or an empty vector as control) into Eµ-myc transgenic fetal liver cells
and their subsequent propagation in lethally irradiated recipients, at manifestation (n = 3
samples each). Representative photomicrographs related to the data set in Figure 4B.
(D) Adoptive transfer of GFP-transduced and PMA-stimulated (as in Figure 4A) Ana-1
macrophages by intravenous injection into control lymphoma-bearing mice. Macrophage
infiltration of lymphoma sites by GFP (insert) and F4/80 immunostaining (red); TGF-β
pathway activation by immunostaining for Smad3-P and PAI-1 in situ; senescence by SA-β-
gal staining (six days after macrophage transfer). Representative photomicrographs of at least
three cases each
(E) Ana-1 macrophages are senescent (as indicated by SA-β-gal staining) at day 7 following
exposure to adriamycin (ADR; 0.2 µg/ml) but not to PMA (as in [D]); therefore, PMA-
exposed macrophages do not account for increased frequencies of SA-β-gal-positive cells
in situ following adoptive transfer. Scale bar = 20 µm (identical magnification throughout the
panel).
(F) Monocyte/macrophage cell counts by 2-colour flow cytometric analysis (using antibodies
against CD11b and F4/80) of peripheral blood samples and lymph node preparations of
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normal wild-type mice 24 hours after intravenous injection of either empty liposomes or
liposome-encapsulated clodronate.
(G) Macrophage infiltration of lymphoma sites by F4/80 immunostaining; TGF-β pathway
activation by immunostaining for Smad3-P in situ; senescence by SA-β-gal staining.
Representative photomicrographs of at least three cases each.
(H) Relative TGF-β1 protein levels (compared to normalized medium-corrected values of
untreated pMP) by ELISA in cell culture supernatants of pMP exposed to PMA and to the
angiotensin-converting enzyme (ACE) inhibitor lisinopril, which reportedly suppresses TGF-
β1 production (Kagami et al., 1994). pMPs were pre-incubated for six hours with lisinopril
(100 µM), PMA (200 ng/ml), or both, or medium only, washed and then exposed to PMA or
left untreated for another 48 hours prior to ELISA; lisinopril was re-added at 24 hours (data
shown reflect triplicates).
(I) Quantification of senescence by SA-β-gal staining in lymphomas arising in mice that were
continuously exposed to lisinopril starting from about four weeks of age (n = 4 individual
mice). Compared to untreated control lymphomas (Figure 1B), lisinopril treatment
significantly reduced the frequency of SA-β-gal-positive cells in lymphomas at manifestation.
(J) Detection of A C E transcripts by RT-PCR in macrophages (Ana-1 cells and two
independent pMP preparations), but not in lymphoma cells (Koca et al., 2007) (n = 3; with
TBP  as an internal control), indicating that lisinopril exerts its inhibitory function in
macrophages, while lymphoma cells do not express the target enzyme.
(K) Detection of TβR-II-ED transcripts by RT-PCR in GFP-positive, but not in GFP-negative
(as assessed by flow cytometry, data not shown) lymphoma samples derived from the TβR-II-
ED/GFP-transduced FLC transplantation experiment (Figure 4E); shown are two
representative cases each (with TBP as an internal control).
(L) TGF-β pathway activation analyzed by immunohistochemical staining for Smad3-P, and
frequency of senescent cells by SA-β-gal staining in lymph node sections obtained at
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manifestation from TβR-II-ED/GFP-positive vs. negative (mock) control lymphomas as in
Figure 4E; note that macrophage infiltration (by F4/80 staining) remained unchanged
(representative photomicrographs from at least three samples per genotype tested).
(M) Curve fitting analysis of the mean frequencies of lymphoma-infiltrating macrophages and
of the corresponding mean SA-β-gal-positive cells (as shown in Figure 1B and 1C, Figure 4
and Figure S1D); i.e. calculated from the data points (black diamonds) referring to bcl2
infection vs. empty vector, Ana-1 macrophage transfer vs. no transfer, clodronate treatment
vs. empty liposomes, and mock infection as compared to the corresponding TβR-II-ED/GFP
infection (green diamond) and as compared to Suv39h1- lymphomas (red diamond). Note the
high coefficient of determination (R2) for the fitted black coordinates as opposed by the
outlier positions of the scenarios depicted in green and red, respectively.
(N) Apoptotic body-induced macrophage-derived TGF-β secretion suppresses lymphoma cell
colony formation: matching the SA-β-gal frequencies measured in the respective single cell
preparations of the colonies presented here (as shown in Figure 4H), GFP-positive
control;bcl2 lymphoma cells co-cultured with primary peritoneal macrophages (pMP) in
semi-solid methylcellulose formed less and on average much smaller colonies when pMP
were pre-activated by 4-OHT-apoptotic Eµ-myc;p53ERTAM/(-) lymphoma cells (as compared to
solvent-treated lymphoma cells or to native pMP that were not pre-exposed to lymphoma
cells). Importantly, the observed growth suppression was largely prevented by co-incubation
with the TGF-β receptor type I inhibitor SD-208 (TGFR-I; 500 nM). Note that some larger
colonies in the 4-OHT/no TGFR-I setting may have escaped TGF-β-mediated growth
suppression by rapid expansion out of the close proximity to adjacent macrophages, and, thus,
potentially out of their senescence-effective TGF-β gradient. Experimental conditions with
native pMP and exogenous addition of TGF-β1 (100 pM) are provided as an additional
control for comparison. Shown are representative fluorescence micrographs of three
independent experiments.
All numbers indicate the mean values ± SD; “*” reflects P < 0.05; “n.s.” not significant. All
scale bars in this figure represent 50 µm.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
 In vivo-Treatments
In some experiments, mice were exposed to the following drug treatments until
lymphomas were harvested: 5-bromo-2’-deoxyuridine (BrdU, 100 mg/kg, supplemented with
10 mg/kg 5-fluoro-2’-deoxyuridine [FDU]; BrdU in situ detection kit, BD Pharmingen)
administered intraperitoneally (i.p.) 24 hours prior to lymphoma isolation, or 1 mg tamoxifen
(10 mg/ml in peanut oil; Sigma-Aldrich) daily i.p. for five days starting at lymphoma
manifestation (Martins et al., 2006) (with peanut oil as solvent control), or liposome-
encapsulated clodronate, produced as described (Aichele et al., 2003), or empty liposomes as
control by intravenous administration (10 µl/g body weight of a 1:1 dilution of a liposome
stock adjusted to an OD600 [optical density] of 1.2) every 48 hours up to three times, or
caffeine (0.4 mg/ml in drinking water; Sigma-Aldrich) starting after weaning (Kramata et al.,
2005), or N-acetyl-cysteine (NAC; as a 0.5% solution in drinking water; Hexal) starting at
mid-embryonic stage (Reimann et al., 2007), or lisinopril (60 mg/l in drinking water; Sigma-
Aldrich) starting at around four weeks of age, with all orally applicable drugs provided ad
libitum.
Immunoblotting, Immunoprecipitation and Antibody List
Briefly, whole-cell extracts for immunoblotting (IB) were generated by lysing cells in
SDS sample buffer (60 mM Tris-HCl at pH 6.8, 10% glycerol, 2% SDS, and 5% 2-
mercaptoethanol), and aliquots corresponding to 50-200 µg of protein were resolved on SDS-
polyacrylamide gels and transferred to Immobilon P membranes (Millipore). For HA-
Suv39h1/Smad IP, 200 µg of protein lysates (produced by lysing cells in 200 mM NaCl,
50 mM Tris, pH 8.0, 5 mM EDTA, 1% Triton-X, 10% glycerol, 1 mM sodium orthovanadate,
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2 mM DTT, 1.5 µg/ml aprotinin, 0.3 µg/ml pefabloc and 6 µg/ml leupeptin) were incubated
with a 1:40 dilution of anti-HA or IgG-control antibodies at 4°C for 3 hours, and IB was
carried out as described (Schmitt et al., 1999), and blots were probed with Smad antibodies.
Immunophenotyping by flow cytometry as well as antigen detection by immunofluorescence
(IF), immunohistochemistry (IHC), immunoblotting (IB), and immunoprecipitation (IP) was
carried out with antibodies against 53BP1 (sc-22760, Santa-Cruz Biotechnology [SCBT],
1:1000 dilution), 53BP1-P-Ser25 (NB 100-2279, Novus Biologicals, 1:1000), Annexin V (no.
556419, BD Pharmigen [BDP], 1:200), ARF (ab80, Abcam, 1:1000), Bcl2 (no. 554087, BDP,
1:2000), ATM (2C1, GeneTex, 1:1000), ATM-P-Ser1987 (no. 4526, Cell Signaling
Technology [CST], 1:1000), Bcl6 (594, Dako, 1:25), CD10 (56C6, Novocastra, 1:50), CD68
(PG-M1, Dako, 1:50), cleaved Caspase 3/Asp175 (no. 9661, CST, 1:200), Cyclin A (CY-A1,
Sigma, 1:1000), estrogen receptor (sc-542, SCBT, 1:100), F4/80 (BM8, eBioscience, 1:50),
hemagglutinin HA.11 (16B12, Covance, 1:1000), H2A.X-P-Ser139 (i.e. γ-H2AX) (JBW301,
Upstate Biotech, 1:100), H3K4me3 (no. 9751, CST, 1:1000), H3K9ac (no. 9649, CST,
1:1000), H3K9me3 (ab8898, Abcam, 1:1000), H3K27me3 (provided by T.J., 1:1000),
H4K20me3 (ab9053, Abcam, 1:1000), HP1γ (no. 07-332, Upstate Biotech, 1:1000), Ki67
(Tec3, Dako, 1:2000, and MIB-1, Dako, 1:2000), Mum1/IRF4 (kindly provided by B. Falini;
1:20), c-Myc (N-262, SCBT, 1:1000), p15INK4b (no. 4822, CST, 1:1000), p16INK4a (M-156 and
F-12, SCBT, 1:500 and 1:2000, respectively), p21CIP1 (C-19, SCBT, 1:500), p53 (CM5,
Novocastra, 1:2000), p53-P-Ser18 (no. 9284, CST, 1:1000), PAI-1 (sc-8979, SCBT, 1:50),
Puma (ab9643, Abcam, 1:2000), Rb (G3-245, BDP, 1:100), Smad2-P-Ser465/Ser467
(no. 3108, CST, 1:1000), Smad3-P-Ser423/425/Smad1-P-Ser463/465 (no. 9514, CST, 1:20),
Smad4 (no. 9515, CST, 1:1000), TGF-β1 (no. 3709, CST, 1:50), and α-tubulin (T5168,
Sigma-Aldrich, 1:8000). Immunophenotyping by flow cytometry was conducted with
antibodies against B220 (CD45; RA3-6B2, BDP, 1:200), IgM (no. 553437, BDP, 1:200),
Thy1.2 (CD90.2; no. 553003, BDP, 1:100), CD11b (M1/70, BDP, 1:200) and CD206 (clone
MR5D3, no. MCA2235A488, AbD Serotec, 1:20). Where required, corresponding
peroxidase- and or fluorescence-conjugated secondary antibodies (GE Healthcare, Molecular
Probes, SCBT) were used. Staining intensities of Smad3-P or PAI-1 in situ were semi-
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quantitatively assessed (- vs. +, ++ or +++; converted into numeric values 0, 1, 2 or 3 to
calculate a mean in some experiments [where a value of around 0.5 would translate into (+)]).
TGF-β1 protein concentrations were also measured by ELISA (Quantikine, R&D Systems) in
HCl-activated cell-free culture supernatant in accordance with the manufacturer’s protocol.
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